Assessment of NanoString technology as a tool for profiling circulating miRNA in maternal blood during pregnancy

Abstract

Aim: Circulating maternal MicroRNA (miRNA) is a promising source of biomarkers for antenatal diagnostics. NanoString nCounter is a popular global screening tool due to its simplicity and ease of use, but there is a lack of standardisation in analysis methods. We examined the effect of user-defined variables upon reported changes in maternal blood miRNA during pregnancy.

Methods: Total RNA was prepared from the maternal blood of pregnant and control rats. miRNA expression was profiled using Nanostring nCounter. Raw count data were processed using nSolver using different combinations of normalisation and background correction methods as well as various background thresholds. A panel of 14 candidates in which changes were supported by multiple analysis workflows was selected for validation by RT-qPCR. We then reverse-engineered the nSolver analysis to gain further insight.

Results: Thirty-one putative differentially expressed miRNAs were identified by nSolver. However, each analysis workflow produced a different set of reported biomarkers and none of them was common to all analysis methods. Four miRNAs with known roles in pregnancy (miR-183, miR-196c, miR-431, miR-450a) were validated. No single nSolver analysis workflow could successfully identify all four validated changes. Reverse engineering revealed errors in nSolver data processing which compound the inherent problems associated with background correction and normalisation.

Conclusion: Our results suggest that user-defined variables greatly influence the output of the assay. This highlights the need for standardised nSolver data analysis methods and detailed reporting of these methods. We suggest that investigators in the future should not rely on a single analysis method to identify changes and should always validate screening results.

Keywords

Micro RNA / expression profiling / blood biomarker / pregnancy

References

[1] Kang L,Jing W,Liu M.Global, regional, and national incidence and mortality of congenital birth defects from 1990 to 2019.Eur J Pediatr2023;182:1781-92

[2] Pagel C,Crowe S,Cunningham D.A mortality risk model to adjust for case mix in UK paediatric cardiac surgery.Health Serv Deliv Res2013;1

[3] Ferentzi H,Rosenthal LM,Schmitt KRL.Long-term early development research in congenital heart disease (LEADER-CHD): a study protocol for a prospective cohort observational study investigating the development of children after surgical correction for congenital heart defects during the first 3 years of life.BMJ Open2017;7:e018966 PMCID:PMC5770821

[4] Plana MN,Suresh G,Thangaratinam S.Pulse oximetry screening for critical congenital heart defects.Cochrane Database Syst Rev2018;3:CD011912 PMCID:PMC6494396

[5] Bonnet D.Impacts of prenatal diagnosis of congenital heart diseases on outcomes.Transl Pediatr2021;10:2241-9 PMCID:PMC8429871

[6] van Nisselrooij AEL,Clur SA.Why are congenital heart defects being missed?.Ultrasound Obstet Gynecol2020;55:747-57 PMCID:PMC7317409

[7] Sharland G.Routine fetal cardiac screening: what are we doing and what should we do?.Prenat Diagn2004;24:1123-9

[8] O'Brien J,Zayed Y.Overview of microRNA biogenesis, mechanisms of actions, and circulation.Front Endocrinol (Lausanne)2018;9:402 PMCID:PMC6085463

[9] Ortiz-Quintero B.Extracellular microRNAs as intercellular mediators and noninvasive biomarkers of cancer.Cancers (Basel)2020;12:3455 PMCID:PMC7699762

[10] Gu H,Xue J.Expression profile of maternal circulating microRNAs as non-invasive biomarkers for prenatal diagnosis of congenital heart defects.Biomed Pharmacother2019;109:823-30

[11] Zhu S,Zhu J.Identification of maternal serum microRNAs as novel non-invasive biomarkers for prenatal detection of fetal congenital heart defects.Clin Chim Acta2013;424:66-72

[12] Zedníková I,Šeda O.Genome-wide miRNA profiling in plasma of pregnant women with down syndrome fetuses.Mol Biol Rep2020;47:4531-40 PMCID:PMC7295716

[13] Erturk B,Aykut A.Prenatal evaluation of microRNA expressions in pregnancies with down syndrome.Biomed Res Int2016;2016:5312674 PMCID:PMC4823505

[14] Zbucka-Kretowska M,Paczkowska-Abdulsalam M.Prenatal circulating microRNA signatures of foetal down syndrome.Sci Rep2019;9:2394 PMCID:PMC6382869

[15] Balaraman S,Tseng AM.Plasma miRNA profiles in pregnant women predict infant outcomes following prenatal alcohol exposure.PLoS One2016;11:e0165081 PMCID:PMC5102408

[16] Yin Y,Yu H,Zhou R.Circulating microRNAs as biomarkers for diagnosis and prediction of preeclampsia: a systematic review and meta-analysis.Eur J Obstet Gynecol Reprod Biol2020;253:121-32

[17] Kim SH,Binkhamis R.Maternal plasma miRNAs as potential biomarkers for detecting risk of small-for-gestational-age births.EBioMedicine2020;62:103145 PMCID:PMC7708817

[18] Elovitz MA,Bastek J.Can microRNA profiling in maternal blood identify women at risk for preterm birth?.Am J Obstet Gynecol2015;212:782.e1-5

[19] Adamova P,Powell AK.Are there foetal extracellular vesicles in maternal blood?.J Mol Med (Berl)2023;101:65-81 PMCID:PMC9977902

[20] Sheller-Miller S,Choi C.Cyclic-recombinase-reporter mouse model to determine exosome communication and function during pregnancy.Am J Obstet Gynecol2019;221:502.e1-502.e12

[21] Nguyen SL,Greenberg JW.Integrins mediate placental extracellular vesicle trafficking to lung and liver in vivo.Sci Rep2021;11:4217 PMCID:PMC7893009

[22] Sarker S,Perez A.Placenta-derived exosomes continuously increase in maternal circulation over the first trimester of pregnancy.J Transl Med2014;12:204 PMCID:PMC4283151

[23] Salomon C,Scholz-Romero K.Placental exosomes as early biomarker of preeclampsia: potential role of exosomal microRNAs across gestation.J Clin Endocrinol Metab2017;102:3182-94

[24] Sato F,Terasawa K.Intra-platform repeatability and inter-platform comparability of microRNA microarray technology.PLoS One2009;4:e5540 PMCID:PMC2677665

[25] Cuk K,Heil J.Circulating microRNAs in plasma as early detection markers for breast cancer.Int J Cancer2013;132:1602-12

[26] Wang J,Sen S.MicroRNA as biomarkers and diagnostics.J Cell Physiol2016;231:25-30 PMCID:PMC8776330

[27] Hong LZ,Zou R.Systematic evaluation of multiple qPCR platforms, nanostring and miRNA-Seq for microRNA biomarker discovery in human biofluids.Sci Rep2021;11:4435 PMCID:PMC7904811

[28] Potla P,Kapoor M.A bioinformatics approach to microRNA-sequencing analysis.Osteoarthr Cartil Open2021;3:100131 PMCID:PMC9718162

[29] Eastel JM,Lee NL.Application of Nanostring technologies in companion diagnostic development.Expert Rev Mol Diagn2019;19:591-8

[30] Monsellato I,Cassinotti E.Expression levels of circulating miRNAs as biomarkers during multimodal treatment of rectal cancer - TiMiSNAR-mirna: a substudy of the TiMiSNAR Trial (NCT03962088).Trials2020;21:678 PMCID:PMC7382047

[31] Gray C,Patel R,Vickers MH.Maternal plasma miRNAs as biomarkers during mid-pregnancy to predict later spontaneous preterm birth: a pilot study.Sci Rep2017;7:815 PMCID:PMC5429750

[32] Spiliopoulos M,Al-Kouatly HB.MicroRNA analysis in maternal blood of pregnancies with preterm premature rupture of membranes reveals a distinct expression profile.PLoS One2022;17:e0277098 PMCID:PMC9632843

[33] Filardi T,Grieco GE.Identification and validation of miR-222-3p and miR-409-3p as plasma biomarkers in gestational diabetes mellitus sharing validated target genes involved in metabolic homeostasis.Int J Mol Sci2022;23:4276 PMCID:PMC9028517

[34] Pillay P,Moodley J.Placental exosomes and pre-eclampsia: maternal circulating levels in normal pregnancies and, early and late onset pre-eclamptic pregnancies.Placenta2016;46:18-25

[35] Foye C,David W.Comparison of miRNA quantitation by Nanostring in serum and plasma samples.PLoS One2017;12:e0189165 PMCID:PMC5718466

[36] Géczi D,Szilágyi M.Analysis of circulating miRNA profile in plasma samples of glioblastoma patients.Int J Mol Sci2021;22:5058 PMCID:PMC8151942

[37] Permuth JB,Williams SL.A pilot study to troubleshoot quality control metrics when assessing circulating miRNA expression data reproducibility across study sites.Cancer Biomark2022;33:467-78 PMCID:PMC9428925

[38] Desai CS,Bellio MA.Characterization of extracellular vesicle miRNA identified in peripheral blood of chronic pancreatitis patients.Mol Cell Biochem2021;476:4331-41

[39] Oikonomopoulos A,Joshi S,Iliopoulos D.Identification of circulating microRNA signatures in Crohn’s disease using the nanostring ncounter technology.Inflamm Bowel Dis2016;22:2063-9

[40] Foley HB,Eckel SP.Extracellular vesicle-enriched miRNA profiles across pregnancy in the MADRES cohort.PLoS One2021;16:e0251259 PMCID:PMC8115775

[41] Waggott D,Yin S,Liu FF.Nanostringnorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data.Bioinformatics2012;28:1546-8 PMCID:PMC3356845

[42] NanoString. Gene expression data analysis guidelines. Available from: https://nanostring.com/wp-content/uploads/Gene_Expression_Data_Analysis_Guidelines.pdf. [Last accessed on 5 Sep 2024].

[43] NanostringTechnologies. TECH NOTE: nCounter® miRNA expression analysis in plasma and serum samples. 2019. Available from: https://university.nanostring.com/tech-note-mirna-expression-analysis-in-plasmaserum-samples/894685. [Last accessed on 5 Sep 2024].

[44] Andersen CL,Ørntoft TF.Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets.Cancer Res2004;64:5245-50

[45] Ajayi AF.Staging of the estrous cycle and induction of estrus in experimental rodents: an update.Fertil Res Pract2020;6:5 PMCID:PMC7071652

[46] Wu J,Xiang YB.Intra-individual variation of miRNA expression levels in human plasma samples.Biomarkers2018;23:339-46 PMCID:PMC6069601

[47] Blondal T,Baker A.Assessing sample and miRNA profile quality in serum and plasma or other biofluids.Methods2013;59:S1-6

[48] Kirschner MB,Edelman JJ.Haemolysis during sample preparation alters microRNA content of plasma.PLoS One2011;6:e24145

[49] Aguilera-Rojas M,Stein T,Kohn B.Systematic analysis of different degrees of haemolysis on miRNA levels in serum and serum-derived extracellular vesicles from dogs.BMC Vet Res2022;18:355 PMCID:PMC9494854

[50] Shah JS,Marsh DJ.Comparison of methodologies to detect low levels of hemolysis in serum for accurate assessment of serum microRNAs.PLoS One2016;11:e0153200 PMCID:PMC4824492

[51] Jolliffe IT.Principal component analysis: a review and recent developments.Philos Trans A Math Phys Eng Sci2016;374:20150202 PMCID:PMC4792409

[52] Chan SF,Goh KK.Preanalytic methodological considerations and sample quality control of circulating miRNAs.J Mol Diagn2023;25:438-53

[53] Sunderland N,Barwari T.MicroRNA biomarkers and platelet reactivity.Circ Res2017;120:418-35

[54] Teruel-Montoya R,Abraham S.MicroRNA expression differences in human hematopoietic cell lineages enable regulated transgene expression.PLoS One2014;9:e102259 PMCID:PMC4100820

[55] Zampetaki A,Drozdov I.Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes.Circ Res2010;107:810-7

[56] Livak KJ.Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method.Methods2001;25:402-8

[57] Yuan JS,Chen F.Statistical analysis of real-time PCR data.BMC Bioinformatics2006;7:85 PMCID:PMC1395339

[58] Rieu I.Real-time quantitative RT-PCR: design, calculations, and statistics.Plant Cell2009;21:1031-3 PMCID:PMC2685626

[59] Stefanski AL,Peterson LK.Murine trophoblast-derived and pregnancy-associated exosome-enriched extracellular vesicle microRNAs: implications for placenta driven effects on maternal physiology.PLoS One2019;14:e0210675 PMCID:PMC6366741

[60] Zhang J,Cai R.miR-196a-5p-Rich extracellular vesicles from trophoblasts induce M1 polarization of macrophages in recurrent miscarriage.J Immunol Res2022;2022:6811632 PMCID:PMC9153387

[61] Zhao G,Jiang K.MiRNA profiling of plasma-derived exosomes from dairy cows during gestation.Theriogenology2019;130:89-98

[62] Akbar R,Rahman TU.miR-183-5p regulates uterine receptivity and enhances embryo implantation.J Mol Endocrinol2020;64:43-52

[63] Lykoudi A,Lambrou GI.Dysregulated placental microRNAs in early and late onset preeclampsia.Placenta2018;61:24-32

[64] Yang X.MicroRNA-431 affects trophoblast migration and invasion by targeting ZEB1 in preeclampsia.Gene2019;683:225-32

[65] Thottakara T,Krämer E,Carrier L.A novel miRNA screen identifies miRNA-4454 as a candidate biomarker for ventricular fibrosis in patients with hypertrophic cardiomyopathy.Biomolecules2021;11:1718 PMCID:PMC8615621

[66] Kim N,Kim YJ.Serum microRNA as a potential biomarker for the activity of thyroid eye disease.Sci Rep2023;13:234 PMCID:PMC9816116

[67] Arora S,Holland EC.Variability in estimated gene expression among commonly used RNA-seq pipelines.Sci Rep2020;10:2734 PMCID:PMC7026138